Compare

Sandoz Group AG/€SDZ

1D1W1M3M6MYTD1Y5YMAX

About Sandoz Group AG

Sandoz Group AG operates in the pharmaceutical industry, specializing in the development, manufacturing, and distribution of generic medicines and biosimilars. The company's product portfolio includes a wide range of therapeutic areas, such as antibiotics, oncology, and cardiovascular treatments. Sandoz was founded as part of a broader restructuring that involved the separation from Novartis in 2022, with a focus on enhancing the accessibility of high-quality healthcare solutions. Headquartered in Switzerland, Sandoz has a significant global presence with operations spanning across numerous countries. The company emphasizes cost-effective healthcare, leveraging a substantial manufacturing and research capacity to maintain competitive strengths in the global pharmaceutical market.
Ticker
€SDZ
Sector
Health
Primary listing
XGAT
Employees
20,000
Headquarters
Basel, Switzerland
Website
www.sandoz.com

Sandoz Group AG Metrics

BasicAdvanced
€39B
68.92
€1.31
0.49
€0.87
0.96%

Bulls say / Bears say

Biosimilars are driving growth: sales rose 17% at constant currencies in Q3 and made up 34% of revenue, while North American sales grew 20%. This growing share gives Sandoz a faster-growing engine than its more pressured generics business. (Sandoz)
Sandoz has expanded its biosimilar pipeline to 40 assets and aims for more than 100 products by 2040. It targets mid-to-high single-digit annual sales growth through 2030, offering a sizeable long-term growth opportunity if it can deliver the launches. (Sandoz, Reuters)
Despite lowering its sales outlook, Sandoz raised its 2026 core EBITDA margin forecast to 23.0–23.5%, from 21.7% in 2025, and said its earnings-per-share outlook had improved. Better product mix and operating performance could support further profit growth. (Reuters, Sandoz)
Sandoz cut its 2026 sales-growth guidance to 5–6% from mid-to-high single digits after a third-quarter sales miss. Temporary biosimilar supply constraints and weaker-than-expected conditions in Germany could limit near-term growth. (Reuters)
Pricing and competition weigh on the business: Sandoz reported 5% price erosion over the first nine months, while low-priced Chinese antibiotics are putting pressure on its penicillin supply chain. Reuters reported that the Kundl plant’s European production is not commercially sustainable without better pricing or policy support. (Sandoz, Reuters)
US state enforcers announced an in-principle settlement of about $469 million to resolve allegations of generic-drug price fixing and related claims involving Sandoz entities. The agreement remains contingent on required approvals and brings financial, compliance and reputational risk. (California Department of Justice)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.

Funds containing Sandoz Group AG

AllEURUSDGBP
Funds
Fund name
Fund size
€SDZ weighting
HSBC MSCI Europe Islamic Screened$HIEU
€144M0.66%
HSBC MSCI Europe Islamic Screened£HIPS
€144M0.66%
Xtrackers MSCI World Health Care$XDWH
$4.1B0.45%
Xtrackers MSCI World Health Care£XWHS
$4.1B0.45%
SPDR MSCI World Health Care£HEAW
$708M0.45%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.